All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What does the future of T-cell lymphoma management look like?

During Lymphoma Leukemia & Myeloma 2021 Virtual Congress, the Lymphoma Hub was pleased to speak to Jia Ruan, Weill Cornell Medicine, New York, US. We asked, What does the future of T-cell lymphoma management look like?

What does the future of T-cell lymphoma management look like?

Ruan describes a promising future for T-cell lymphoma with increasingly personalized treatment, driven by precision medicine and a growing list of targeting agents. She outlines the current treatment approach, explains the impact of biological agents such as brentuximab, and describes how other novel targeted agents affect the management landscape. Finally, Ruan highlights that future studies should focus on optimizing novel agent combinations, such as romidepsin + Lenalidomide or romidepsin + Azacitidine.

 

Share: